Multi-vitamins, HAART and HIV/AIDS in Uganda

Launched by HARVARD SCHOOL OF PUBLIC HEALTH (HSPH) · Oct 25, 2010

Keywords

ClinConnect Summary

Antiretroviral therapy, gradually becoming the standard of care in developing countries, confers enormous benefits and yet substantial morbidity remains in human immunodeficiency virus (HIV) positive populations. Multivitamin supplements have immune-enhancing effects, and supplements were found to improve immunologic status and reduce morbidity and mortality among HIV-positive Tanzanian women in pre-highly active anti-retroviral therapy (HAART) stages of disease. These supplements are thought to be required to restore adequate nutrient levels in the context of HIV infection.

This study wil...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • men or women aged \>=18 years old
• • HIV-positive
• • initiating anti-retroviral therapy at the time of randomization or have been on highly active anti-retroviral therapy (HAART) for no more than 6 months
• • have no intention of migrating, or re-locating \>= 20 km outside of the Infectious Disease Institute (IDI), or Kiswa Health Center within the next 18 months after enrollment
• • agree to allow home visit(s) and subsequent follow-up contacts as part of the study
• • provide written informed consent
• Exclusion Criteria:
• • pregnant Women
• • individuals from whom we are unable to obtain written informed consent will be excluded from the study. For example, patients that are extremely ill and unable to consent will be excluded.